参考文献/References:
[1] Li D, Ling Z, Li Z, et al. Association of CKD-MBD markers with all-cause mortality in prevalent hemodialysis patients: a cohort study in Beijing[J]. Plos One, 2017, 12(1):e0168537.
[2] 刘晓华, 李党生. 血脂康胶囊对高脂血症的疗效及对白介素-6和白介素-18的影响研究[J]. 临床合理用药杂志, 2012, 5(30):8-9.
[3] Yamada S, Giachelli CM. Vascular calcification in CKD-MBD: roles for phosphate, FGF23, and Klotho[J]. Bone, 2017, 100:87-93.
[4] 何国秋.马来酸桂哌齐特对脑梗死老年患者可溶性肿瘤坏死因子相关凋亡诱导配体、骨保护素的影响[J]. 中国老年学杂志, 2013, 33(24): 6266-6267.
[5] 刘俊孚, 牛丽婷, 徐 江. 超敏C反应蛋白、白细胞介素-12、白细胞介素-18在冠心病患者血清中的表达情况及意义[J]. 中国医药导报, 2012, 9(30):59-60.
[6] Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters[J]. Kidney International, 2017, 92(1):26.
[7] 胡顺金, 王 东, 张 芮, 等. 蓉黄颗粒对非透析CKD-MBD肾虚湿热证患者血清FGF23、FGFRs、Klotho蛋白的影响[J]. 南方医科大学学报, 2018, 38(12): 66-67.
[8] 刘 洪, 冯小兰, 袁晓玲, 等. 糖尿病患者血清sKlotho、NGAL、MCP-1和TGF-β1的表达及意义[J]. 河北医药, 2019, 41(2): 186-188.
[9] 杨肖红, 张 昆. 淫羊藿对糖尿病骨质疏松患者骨保护素水平的影响[J]. 山东医药, 2010, 50(49): 66-67.
[10] Apetrii M, Goldsmith D, Nistor I, et al. Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD)-A systematic review and meta-analysis[J]. Plos One, 2017, 12(11):e0187025.
[11] Cozzolino M. CKD-MBD KDIGO guidelines: how difficult is reaching the 'target'?[J]. Clinical Kidney Journal, 2018, 11(1):70-72.
[12] 李旭光, 郭宏林, 上官改珍,等. 2型糖尿病肾病患者血清IL-18、IL-6、NO与ET的水平变化[J]. 陕西医学杂志, 2012, 41(3):356-357.
[13] 赵建勋, 李 霞, 吴大英. 自拟中药内服联合保留灌肠对溃疡性结肠炎IL-10、IL-18的影响[J]. 陕西中医, 2015, 36(6):709-710.